Abbreviations and Acronyms:BSCR (birdshot chorioretinopathy), FA (fluorescein angiography), ILM (internal limiting membrane), OCTA (OCT angiography), SS-OCTA (swept-source OCTA)
- Retinal vasculitis.Int Ophthalmol Clin. 2005; 45: 99-113
- Referral patterns of uveitis in a tertiary eye care center.Arch Ophthalmol. 1996; 114: 593-599
- Retinal vasculitis.Curr Opin Rheumatol. 2016; 28: 228-235
- Retinal periphlebitis and retinitis in multiple sclerosis. I. Pathologic characteristics.Ophthalmology. 1984; 91: 255-262
- Sarcoidosis with optic nerve and retinal involvement.Arch Ophthalmol. 1976; 94: 945-950
- Pathology of pars planitis.Am J Ophthalmol. 1978; 86: 762-774
- Histopathology of birdshot retinochoroidopathy.Br J Ophthalmol. 2002; 86: 1439-1441
- A clinical approach to the diagnosis of retinal vasculitis.Int Ophthalmol. 2010; 30: 149-173
- Optical coherence tomography angiography in patients with Behçet uveitis.Retina. 2017; 37: 1678-1691
- Fluorescein angiography complication survey.Ophthalmology. 1986; 93: 611-617
- Retinal vascular layers imaged by fluorescein angiography and optical coherence tomography angiography.JAMA Ophthalmol. 2015; 133: 45-50
- Pearls and pitfalls of optical coherence tomography angiography in the multimodal evaluation of uveitis.J Ophthalmic Inflamm Infect. 2017; 7: 20-32
- Optical coherence tomography angiography: a comprehensive review of current methods and clinical application.Prog Retin Eye Res. 2017; 60: 66-100
- Quantifying retinal microvascular changes in Uveitis using spectral-domain optical coherence tomography angiography.Am J Ophthalmol. 2016; 171: 101-112
- Quantitative optical coherence tomography angiography of choroidal neovascularization in age-related macular degeneration.Ophthalmology. 2014; 121: 1435-1444
- New insights on ocular sarcoidosis: an optical coherence tomography angiography study.Ocul Immunol Inflamm. 2019; 27: 1057-1066
- Comparison between optical coherence tomography angiography and fluorescein angiography findings in retinal vasculitis.Int J Retina Vitreous. 2018; 4: 15
- Widefield OCT angiography of idiopathic retinal vasculitis, aneurysms, and neuroretinitis.Ophthalmol Retina. 2017; 1: 567-569
- Evaluation of vascular changes in intermediate uveitis and retinal vasculitis using swept-source wide-field optical coherence tomography angiography.Br J Ophthalmol. 2019; 103: 1289-1295
- Swept-source OCT angiography of the retinal vasculature using intensity differentiation-based optical microangiography algorithms.Ophthalmic Surg Lasers Imaging Retina. 2014; 45: 382-389
- Ultrahigh-speed swept-source OCT angiography in exudative AMD.Ophthalmic Surg Lasers Imaging Retina. 2014; 45: 496-505
- Standardization of Uveitis nomenclature (SUN) working group. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop.Am J Ophthalmol. 2005; 140: 509-516
- Distribution of diabetic neovascularization on ultra- widefield fluorescein angiography and on simulated widefield OCT angiography.Am J Ophthalmol. 2019; 207: 110-120
- Non-invasive method of monitoring retinal vasculitis in patients with birdshot chorioretinopathy using optical coherence tomography.Br J Ophthalmol. 2018; 102: 815-820
- Retinal vasculitis imaging by adaptive optics.Ophthalmology. 2014; 121: 1311-1312
Publication stageIn Press Journal Pre-Proof
Research supported by grants from the National Eye Institute ( R01EY024158 , R01EY028753 ), Carl Zeiss Meditec , Inc., the Salah Foundation , an unrestricted grant from the Research to Prevent Blindness , Inc., and the National Eye Institute Center Core Grant ( P30EY014801 ) to the Department of Ophthalmology, University of Miami Miller School of Medicine . The funding organizations had no role in the design or conduct of this research.
Disclosure(s): All authors have completed and submitted the ICMJE disclosures form.
The author(s) have made the following disclosure(s): J.L.D.: Rresearch grant funding -- Biogen, EyePharma, Johns Hopkins University; Consultant – Kodiak, 4D Molecular Therapeutics. G.G.: Research support -- Carl Zeiss Meditec, Inc. G.G. and the University of Miami co-own a patent that is licensed to Carl Zeiss Meditec, Inc. P.J.R.: Research support -- Carl Zeiss Meditec, Inc, Stealth BioTherapeutics; Consultant -- Apellis, Biogen, Boehringer-Ingelheim, Carl Zeiss Meditec, Chengdu Kanghong Biotech, EyePoint, Ocunexus Therapeutics, Ocudyne, Unity Biotechnology; Equity interest -- Apellis, Valitor, Verana Health, Ocudyne. T.A.B.: Research funding from Klorfine Foundation; consulatant -- Adverum Biotechnologies, Allergan, B+L/Valeant Pharmaceuticals, Beaver Visitec, Clearside Biomedical, Inc., Eyepoint Pharmaceuticals, Genentech, Novartis, RegenexBio; member of the Data Safety Monitoring Committee at Applied Genetic Technologies Corp., and Novartis.
HUMAN SUBJECTS: Human subjects were included in this study. The human ethics committees at the University of Miami Miller School of Medicine approved the study. All research adhered to the tenets of the Declaration of Helsinki. No study-specific informed consent or authorization was required because it was a retrospective review of images obtained during routine clinical care. However, all patients had signed a consent to undergo SS-OCTA based on the institute protocol for SS-OCTA imaging.
No animal subjects were included in this study.
Conception and design: Noori, Shi, Yang, Gregori, Albini, Rosenfeld, Davis
Data collection: Noori, Shi, Yang, Gregori, Albini, Rosenfeld, Davis
Analysis and interpretation: Noori, Shi, Yang, Gregori, Albini, Rosenfeld, Davis
Obtained funding: N/A
Overall responsibility: Noori, Shi, Yang, Gregori, Albini, Rosenfeld, Davis